Shamburg News · 8-K filed Nov 13, 2026, 8:02 AM EST
Benitec Biopharma Reports Q1 FY2027 Results, Changes Fiscal Year-End to December 31
BNTC · Benitec Biopharma Inc.
- Earnings
- Other event
- Financial statements
- Materiality: high
Benitec Biopharma Inc. reported a net loss of $12.9 million, or $(0.26) per basic and diluted share, for the fiscal quarter ended September 30, 2026, compared with a net loss of $9.0 million, or $(0.22) per share, a year earlier. Research and development expenses rose to $8.6 million from $3.4 million, and cash and cash equivalents were $176.5 million as of September 30, 2026. On November 12, 2026, the Board approved changing the fiscal year-end from June 30 to December 31, creating a six-month transition period from July 1 to December 31, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 5.03, 9.01, accession 0001193125-26-459339.
Written from the filing by Shamburg Markets. Figures are as reported by the company.